Revolutionary Medical Breakthroughs of July 2025: Life-Changing Drugs, Diagnostic Wonders & Public Health Milestones
On July 2, 2025, the FDA granted accelerated approval to linvoseltamab (Lynozyfic), a BCMA-targeting bispecific antibody, for adults with heavily pretreated relapsed/refractory multiple myeloma, after trials showed a 70% response rate. Also on July 2, 2025, the FDA approved sunvozertinib (Zegfrovy) as the first targeted oral therapy for advanced NSCLC with EGFR exon 20 insertion mutations following chemotherapy. In July 2025, the FDA granted Breakthrough Therapy designation to trastuzumab deruxtecan (T-DXd) plus pertuzumab for HER2-positive metastatic breast cancer. Relutrigine (PRAX-562) received FDA Breakthrough Therapy designation for two rare pediatric epileptic encephalopathies (SCN2A and SCN8A) after a Phase 2 study showed
